Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q4 2022 13F Holders as of 31 Dec 2022
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 138,752,791
- Total 13F shares
- 65,900,596
- Share change
- -161,686
- Total reported value
- $1,037,946,141
- Put/Call ratio
- 111%
- Price per share
- $15.75
- Number of holders
- 126
- Value change
- -$2,542,115
- Number of buys
- 56
- Number of sells
- 44
Report period
Q4 2022
Institutions
126
Top holders
10
ACRS full security history
Newer quarter: Q1 2023
Previous quarter: Q3 2022
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock Finance, Inc. |
13F
|
Company |
3.5%
|
4,810,298
|
$75,714,000 | — | 30 Sep 2022 | |
| Venrock Adviser, LLC |
13F
|
Company |
3.3%
|
4,563,962
|
$71,837,000 | — | 30 Sep 2022 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
3.2%
|
4,398,453
|
$69,231,000 | — | 30 Sep 2022 | |
| BVF INC/IL |
13F
|
Company |
2.9%
|
3,976,543
|
$62,591,000 | — | 30 Sep 2022 | |
| Rock Springs Capital Management LP |
13F
|
Company |
2.9%
|
3,961,249
|
$62,350,000 | — | 30 Sep 2022 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.5%
|
3,453,853
|
$54,364,000 | — | 30 Sep 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.1%
|
2,931,709
|
$46,145,000 | — | 30 Sep 2022 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
2%
|
2,808,034
|
$44,198,000 | — | 30 Sep 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
2%
|
2,758,434
|
$43,418,000 | — | 30 Sep 2022 | |
| Commodore Capital LP |
13F
|
Company |
1.7%
|
2,410,622
|
$37,943,000 | — | 30 Sep 2022 | |
| Holocene Advisors, LP |
13F
|
Company |
1.5%
|
2,060,918
|
$32,439,000 | — | 30 Sep 2022 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.3%
|
1,853,251
|
$29,170,000 | — | 30 Sep 2022 | |
| Laurion Capital Management LP |
13F
|
Company |
0.94%
|
1,304,624
|
$20,535,000 | — | 30 Sep 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.94%
|
1,303,027
|
$20,510,000 | — | 30 Sep 2022 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
0.91%
|
1,258,243
|
$19,805,000 | — | 30 Sep 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.85%
|
1,185,178
|
$18,655,000 | — | 30 Sep 2022 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.84%
|
1,168,897
|
$18,399,000 | — | 30 Sep 2022 | |
| FMR LLC |
13F
|
Company |
0.83%
|
1,145,339
|
$18,028,000 | — | 30 Sep 2022 | |
| TCG Crossover Management, LLC |
13F
|
Company |
0.83%
|
1,144,939
|
$18,021,000 | — | 30 Sep 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.81%
|
1,118,417
|
$17,603,000 | — | 30 Sep 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.74%
|
1,028,723
|
$16,192,000 | — | 30 Sep 2022 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.73%
|
1,019,282
|
$16,043,000 | — | 30 Sep 2022 | |
| Vivo Capital, LLC |
13F
|
Company |
0.65%
|
898,631
|
$14,144,000 | — | 30 Sep 2022 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.5%
|
700,000
|
$11,018,000 | — | 30 Sep 2022 | |
| Woodline Partners LP |
13F
|
Company |
0.5%
|
697,007
|
$10,971,000 | — | 30 Sep 2022 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.5%
|
696,171
|
$10,958,000 | — | 30 Sep 2022 | |
| Aisling Capital Management LP |
13F
|
Company |
0.46%
|
634,455
|
$9,986,000 | — | 30 Sep 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.4%
|
553,484
|
$8,712,000 | — | 30 Sep 2022 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.39%
|
543,776
|
$8,559,000 | — | 30 Sep 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.33%
|
452,965
|
$7,129,000 | — | 30 Sep 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.3%
|
422,247
|
$6,646,000 | — | 30 Sep 2022 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.29%
|
408,329
|
$6,427,000 | — | 30 Sep 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.29%
|
402,554
|
$6,337,000 | — | 30 Sep 2022 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.29%
|
400,160
|
$6,300,000 | — | 30 Sep 2022 | |
| Verition Fund Management LLC |
13F
|
Company |
0.27%
|
372,507
|
$5,863,000 | — | 30 Sep 2022 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.25%
|
341,239
|
$5,371,000 | — | 30 Sep 2022 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.25%
|
340,000
|
$5,352,000 | — | 30 Sep 2022 | |
| Walleye Capital LLC |
13F
|
Company |
0.19%
|
269,948
|
$4,249,000 | — | 30 Sep 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.17%
|
233,882
|
$3,682,000 | — | 30 Sep 2022 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.17%
|
233,626
|
$3,677,000 | — | 30 Sep 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.16%
|
221,424
|
$3,485,000 | — | 30 Sep 2022 | |
| HighVista Strategies LLC |
13F
|
Company |
0.16%
|
217,818
|
$3,428,000 | — | 30 Sep 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.15%
|
203,905
|
$3,209,000 | — | 30 Sep 2022 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.14%
|
194,923
|
$3,068,000 | — | 30 Sep 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.12%
|
167,790
|
$2,641,000 | — | 30 Sep 2022 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.12%
|
160,835
|
$2,532,000 | — | 30 Sep 2022 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.1%
|
136,434
|
$2,147,000 | — | 30 Sep 2022 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.08%
|
113,426
|
$1,785,000 | — | 30 Sep 2022 | |
| Swiss National Bank |
13F
|
Company |
0.08%
|
110,500
|
$1,739,000 | — | 30 Sep 2022 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.08%
|
106,756
|
$1,680,339 | — | 30 Sep 2022 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q4 2022
As of 31 Dec 2022,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
126 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,900,596 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., VR Adviser, LLC, RA CAPITAL MANAGEMENT, L.P., Rock Springs Capital Management LP, BVF INC/IL, VANGUARD GROUP INC, Foresite Capital Management IV, LLC, ORBIMED ADVISORS LLC, and BRAIDWELL LP.
This page lists
126
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
124
Q4 2022 holders
126
Holder diff
2
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 Value $ | Q4 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.